- Home
- WFRD vs TVTX Comparison
WFRD vs TVTX Comparison
Compare WFRD & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WFRD | TVTX |
|---|---|---|
| Founded | 1941 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.3B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | WFRD | TVTX |
|---|---|---|
| Price | $77.75 | $40.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 15 |
| Target Price | ★ $93.22 | $37.21 |
| AVG Volume (30 Days) | 896.5K | ★ 1.8M |
| Earning Date | 02-03-2026 | 10-30-2025 |
| Dividend Yield | ★ 1.29% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.52 | N/A |
| Revenue | ★ $4,970,000,000.00 | $435,826,000.00 |
| Revenue This Year | N/A | $120.02 |
| Revenue Next Year | N/A | $37.00 |
| P/E Ratio | $14.06 | ★ N/A |
| Revenue Growth | N/A | ★ 114.22 |
| 52 Week Low | $36.74 | $12.91 |
| 52 Week High | $82.26 | $42.13 |
Technical Indicators
Market Signals| Indicator | WFRD | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.81 | 67.72 |
| Support Level | $75.23 | $33.49 |
| Resistance Level | $81.22 | $42.13 |
| Average True Range (ATR) | 2.13 | 1.92 |
| MACD | -0.30 | 0.39 |
| Stochastic Oscillator | 35.06 | 75.98 |
Price Performance
Historical ComparisonAbout WFRD Weatherford International plc
Weatherford International provides diversified oilfield services across international markets for an array of oilfield types. The firm is a global market leader in artificial lift and tubular running services. Other key product lines include cementing products, directional drilling, and wireline evaluation.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.